Cefaclor Capsules

Compare Cefaclor Capsules  to:
Compare
Compare

Generic Name for Cefaclor Capsules

Cefaclor 250mg, 500mg; caps.

Legal Classification:

Rx

Pharmacological Class for Cefaclor Capsules

Cephalosporin.

Manufacturer of Cefaclor Capsules

Various generic manufacturers

Indications for Cefaclor Capsules

Susceptible infections including otitis media, lower respiratory or urinary tract, pharyngitis/tonsillitis, skin and skin structure.

Adult dose for Cefaclor Capsules

250–500mg every 8 hrs.

Children's dosing for Cefaclor Capsules

<1month: not recommended. ≥1month: 20mg/kg per day in 3 equally divided doses. Otitis media, more serious or less susceptible infections: 40mg/kg per day in 3 equally divided doses (may give in 2 divided doses for pharyngitis or otitis media); max 1g/day.

Also:

Precautions for Cefaclor Capsules

Penicillin or other allergy. Discontinue if colitis occurs and treat. Severe renal dysfunction. GI disease (esp. colitis). Pregnancy (Cat.B). Nursing mothers.

Interactions for Cefaclor Capsules

May cause false (+) Coomb's test or glucose test with Clinitest or Benedict's or Fehling's soln. Potentiated by probenecid. Monitor warfarin. CD: antagonized by concomitant (within 1 hr) aluminum or magnesium-containing antacids.

Adverse Reactions for Cefaclor Capsules

Headache, GI upset, rash, blood dyscrasias, hepatic dysfunction, cough, CNS stimulation, serum-sickness-like reactions.

How is Cefaclor Capsules supplied?

Contact supplier.

Related Disease:

Infections, bacterial~systemic antiinfectives

Related Resources

Cayston inhaled antibiotic approved for cystic fibrosis

February 23, 2010

The FDA has approved Cayston (aztreonam for inhalation solution, from Gilead Sciences) as a treatment to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa.

Phase 3 study of fidaxomicin for clostridium difficile infection (CDI)

February 05, 2010

Optimer Pharmaceuticals announced positive top-line results from the second of two Phase 3 trials evaluating the safety and efficacy of fidaxomicin (OPT-80) in patients with Clostridium difficile Infection (CDI).

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Phase 2 study of Arikace for treatment of pseudomonas lung infections

October 19, 2009

Transave reported additional positive clinical trial results on its lead investigational drug, Arikace (liposomal amikacin for inhalation), an antibiotic to treat chronic lung infections.

Vibativ approved for complicated skin and skin structure infections

September 18, 2009

The FDA has approved Vibativ (telavancin, from Theravance and Astellas), a bactericidal, once-daily injectable lipoglycopeptide antibiotic.